Anpario Regulatory News (ANP)

AGM Statement

Anpario plc, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, is holding its AGM later today, at which Matthew Robinson, Chairman, will make the following statement:

"The Group achieved a strong sales performance in the first half of the year as our business development initiatives deliver and the global agriculture market improves. As such, we are confident of achieving market expectations* for the full year. There are challenges to navigate, however, and the current geopolitical environment makes it difficult to predict if and how our markets could be affected, but our geographic, species and product diversity should help to mitigate against any potential adverse impact.

We are particularly encouraged by a strong performance in the United States with a recovery in the sales of pHorce® to the swine sector and continued growth of Orego-Stim® in the organic egg layer and young cattle segments. India is also delivering a particularly strong performance. Brazil continues to disappoint due to tough local trading conditions.

The Group's business development initiatives include preparation to launch several Bio-Vet products, including leading brands RumenAider®, Generator™ and QuadriCal®, in various territories around the world. Initial discussions with customers and Anpario's global sales team are very encouraging and product registration work is now underway.

Following a strong end to 2024, we have been normalising our inventory levels to support the higher levels of activity seen at the end of last year and the continued growth in 2025. At the same time, we have seen a proportional increase in trade receivables which has absorbed further cash as well as a reduction in trade and other payables, leading to a slight reduction in overall cash. Our cash balance was £9.0m as at 31 May 2025 (£10.5m at 31 December 2024), representing a strong financial position with which to continue to grow the business, both organically and through acquisitions, should the right opportunities arise."

The Company's interim results for the six months period ended 30 June 2025 are expected to be announced on 10 September 2025.

*Analyst consensus for FY 2025 immediately prior to this announcement was Revenue of £44.8m, EBITDA of £7.6m and net cash of £11.9m.